| Autor: |
Muroi M; Research Institute of Pharmaceutical Sciences, Musashino University., Ogura N; LAL Research, Central Research Laboratory, Seikagaku Corporation., Mizumura H; LAL Research, Central Research Laboratory, Seikagaku Corporation., Aketagawa J; Global Business Development & Marketing, Seikagaku Corporation., Oda T; LAL Research, Central Research Laboratory, Seikagaku Corporation., Tanamoto KI; Research Institute of Pharmaceutical Sciences, Musashino University. |
| Jazyk: |
angličtina |
| Zdroj: |
Biological & pharmaceutical bulletin [Biol Pharm Bull] 2019 Dec 01; Vol. 42 (12), pp. 2024-2037. Date of Electronic Publication: 2019 Oct 05. |
| DOI: |
10.1248/bpb.b19-00517 |
| Abstrakt: |
Assays using lysate reagents prepared from horseshoe crab hemocyte extract (limulus amoebocyte lysate, LAL) are commonly and widely used to detect and measure endotoxin in parenteral drugs and medical devices. However, lysate reagents suffer from lot-to-lot variations leading to possible fluctuations in testing. Also, this continued usage of lysate reagents leads to the possible decline of the horseshoe crab population. Recently, a new recombinant chromogenic reagent, PyroSmart, consisting of three recombinant factors was introduced to the market. There are now three recombinant products; two with recombinant factor C reagents and PyroSmart with the complete recombinant LAL system. We evaluated the applicability of the reagent to the harmonized bacterial endotoxins test in the United States, European and Japanese pharmacopeias. The recombinant product showed equivalent potency of thirteen endotoxins from different bacterial strains to conventional chromogenic lysate reagents as long as their assay modes are identical. All analytical characteristics or assay parameters of the reagent satisfied the acceptance criteria which are set for the use for the bacterial endotoxins test filed in the pharmacopeias. All of 109 parenteral drugs tested can be measured with PyroSmart within respective maximum allowable dilutions. The lot-to-lot variation in recovery of endotoxin added in the parenteral drugs for PyroSmart was equal to or less than those of six limulus lysate reagents. In conclusion, the present study suggests that the recombinant reagent, PyroSmart, provide a good alternative to the LAL reagents with better lot-to-lot variation. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
